Comments Leave a Comment

    1-15 of 271 1 2 3 4 ... 16 17 18 »
    1. Mentioned In 271 Articles

    2. The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.

      ...detectable by immunohistochemistry. Importantly, patients with tumors that did not express ALK-I19 and lacked MYCN amplification had an excellent clinical outcome, with 19/19 patients survived at 5-years. In conclusion, ...
      Read Full Article
      Mentions: ALK MYCN
    3. Cross-cohort analysis identifies a TEAD4 ↔ Mycn positive-feedback loop as the core regulatory element of high-risk neuroblastoma.

      ...AD4 ↔ MYCN positive-feedback loop - emerged as the regulatory driver of the high-risk subtype associated with MYCN amplification. Silencing of either gene collapsed MYCN-amplified (MYCNAmp) neuroblastoma transcriptional ...
      Read Full Article
      Mentions: MYCN
    4. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      ...l. Our in vitro and in vivo data demonstrate that DS-3032b reactivates TP53 signaling even in the presence of MYCN amplification in neuroblastoma cells, to reduce proliferative capacity and cause cytotoxicity. ...
      Read Full Article
      Mentions: MYCN
    5. Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site.

      ...ntly correlated with disease-free interval and overall survival (p=0.02 and 0.01 respectively). The amplified MYCN status was also confirmed as correlated with poorer outcomes. Postoperative 123I-MIBG scintigraphy includ...
      Read Full Article
      Mentions: Surgery Imaging MYCN
    6. 1-15 of 271 1 2 3 4 ... 16 17 18 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about MYCN

    1. Children with a MYCN-amplification event, which occurs in about 25 percent of cases, have the poorest prognosis.
      In Loss of a microRNA family, let-7, found key in neuroblastoma
    2. Once a tumor has disrupted let-7 genetically, it doesn't need to amplify MYCN because it doesn't need to sponge let-7.
      In Loss of a microRNA family, let-7, found key in neuroblastoma
    3. We showed that maintenance of high MYCN protein levels is a key issue for this MYCN driven cancer. Neuroblastoma cells often have over 100 copies of the MYCN gene - so they produce an enormous amount of MYCN protein.
      In A way to target the Achilles heel of neuroblastoma